Drug pricing reforms were meant to protect patients — but they may also be reshaping where innovation happens. In this interview, John Stanford of Incubate explains how MFN price controls and regulatory uncertainty ripple through the biotech ecosystem, squeezing small innovators and pushing investment abroad. Moderated by Terzel Vasquez, Producer, STAT Brand Studio.

Read more: https://www.statnews.com/sponsor/2026/03/04/could-u-s-policy-clinch-chinas-grip-on-biotech/